PURPOSE: The goal was to retrospectively review the outcome of patients with cervical lymph node metastases of squamuos cell carcinoma of unknown primary site (CUP) treated with radio(chemo)therapy. PATIENTS AND METHODS: A total of 65 patients with CUP N1-3, M0, treated between 1988 and 2009 were evaluated: 61 patients underwent surgical resection followed by postoperative radio(chemo)therapy, 4 patients received definitive radiochemotherapy. Radiotherapy of bilateral neck nodes + the parapharyngeal region (COMP-RT) was performed in 48 patients (80%) and a unilateral radiotherapy of lymph nodes (UL-RT) in 17 patients (20%). RESULTS: After a median follow-up time of 64 months (range 3-219 months), the estimated 2- and 5-year overall survival (OS) rates were 71 ± 6% and 48 ± 7%, respectively. The recurrent free survival (RFS) rate at 2- and 5-years was 58 ± 6% and 48% ± 7%, respectively. Extracapsular spread, resection status (R0 vs. R1/R2), neck lymph node level (I-III vs. IV-V), and Karnofsky index (60-70 vs. 80-100) were significant prognostic factors for OS and RFS in the univariate analysis. Lower nodal stage (N1/N2a vs. N2b/N2c/N3) was significantly associated with a better OS. Resection status and involvement of lymph node level IV significantly affected the OS and RFS in the multivariate analysis. COMP-RT or concurrent chemotherapy was not associated with a better OS or RFS. CONCLUSION: An advantage of comprehensive radiotherapy or radiochemotherapy compared with unilateral radiotherapy of lymph nodes was not observed.
PURPOSE: The goal was to retrospectively review the outcome of patients with cervical lymph node metastases of squamuos cell carcinoma of unknown primary site (CUP) treated with radio(chemo)therapy. PATIENTS AND METHODS: A total of 65 patients with CUP N1-3, M0, treated between 1988 and 2009 were evaluated: 61 patients underwent surgical resection followed by postoperative radio(chemo)therapy, 4 patients received definitive radiochemotherapy. Radiotherapy of bilateral neck nodes + the parapharyngeal region (COMP-RT) was performed in 48 patients (80%) and a unilateral radiotherapy of lymph nodes (UL-RT) in 17 patients (20%). RESULTS: After a median follow-up time of 64 months (range 3-219 months), the estimated 2- and 5-year overall survival (OS) rates were 71 ± 6% and 48 ± 7%, respectively. The recurrent free survival (RFS) rate at 2- and 5-years was 58 ± 6% and 48% ± 7%, respectively. Extracapsular spread, resection status (R0 vs. R1/R2), neck lymph node level (I-III vs. IV-V), and Karnofsky index (60-70 vs. 80-100) were significant prognostic factors for OS and RFS in the univariate analysis. Lower nodal stage (N1/N2a vs. N2b/N2c/N3) was significantly associated with a better OS. Resection status and involvement of lymph node level IV significantly affected the OS and RFS in the multivariate analysis. COMP-RT or concurrent chemotherapy was not associated with a better OS or RFS. CONCLUSION: An advantage of comprehensive radiotherapy or radiochemotherapy compared with unilateral radiotherapy of lymph nodes was not observed.
Authors: F de Braud; L K Heilbrun; K Ahmed; W Sakr; J F Ensley; J A Kish; E Tapazoglou; M al-Sarraf Journal: Cancer Date: 1989-07-15 Impact factor: 6.860
Authors: Debora Beldì; Barbara A Jereczek-Fossa; Alberto D'Onofrio; Giuseppina Gambaro; Maria Rosaria Fiore; Francesco Pia; Fausto Chiesa; Roberto Orecchia; Marco Krengli Journal: Int J Radiat Oncol Biol Phys Date: 2007-08-22 Impact factor: 7.038
Authors: Basel Al Kadah; Giorgos Papaspyrou; Maximilian Linxweiler; Bernhard Schick; Christian Rübe; Benjamin Simeon Büchler; Marcus Niewald Journal: Eur Arch Otorhinolaryngol Date: 2017-03-17 Impact factor: 2.503
Authors: Jos Straetmans; Julia Vent; Martin Lacko; Ernst-Jan Speel; Christian Huebbers; Robert Semrau; Frank Hoebers; Zlatan Mujagic; Jens-Peter Klussmann; Simon F Preuss; Bernd Kremer Journal: Eur Arch Otorhinolaryngol Date: 2014-03-11 Impact factor: 2.503
Authors: S Tribius; J Sommer; C Prosch; A Bajrovic; A Muenscher; M Blessmann; A Kruell; C Petersen; M Todorovic; P Tennstedt Journal: Strahlenther Onkol Date: 2013-01-27 Impact factor: 3.621